Business Development

Orient Pharma (OP) is Taiwan's first newly built pharmaceutical factory constructed in accordance with PIC/S GMP, EU GMP, and US Food and Drug Administration (FDA) 21 CFR international standards. Orient Pharma (OP) primarily focuses on the research and development of 505(b)(2) new drugs and niche generic drugs, including new dosage forms, new formulations, new indications, and new combination therapies. Its main focus is on the treatment of cardiovascular diseases, endocrine and metabolic diseases, neuroscience, and mental illnesses.

Orient Pharma (OP) is actively expanding its overseas presence, seeking global partners to provide patients with high-quality medical products and achieve the best win-win cooperation model. Its partners are located throughout Asia, Europe, the Americas, Africa, and Oceania. Leveraging the strong team of over 400 sales personnel in OEP Group overseas branches, the company is actively expanding its presence in Taiwan, mainland China, Hong Kong, the Philippines, Vietnam, Singapore, and Malaysia, providing partners with the most professional and locally tailored medical and pharmaceutical services.

By deeply understanding unmet clinical needs, Orient Pharma (OP) will continuously pursue excellence and uphold the spirit of "focusing on self-made products and cultivating professional specialties" to realize the vision of 505(b)(2) medical innovation.